Drug information for VANTIN
Form
Dosage
Status
Therapeutic Equivalence
Active Ingred
Ref.
Sponsor
Document
FOR SUSPENSION; ORAL
EQ 100MG BASE/5ML
Discontinued
CEFPODOXIME PROXETIL
cefpodoxime proxetil
PHARMACIA AND UPJOHN
50675
2007-06-07 Letter
2007-06-07 Label
2004-06-07 Label
2004-06-07 Letter
1999-07-27 Review
1998-11-20 Review
1998-11-20 Letter
1998-11-20 Letter
FOR SUSPENSION; ORAL
EQ 50MG BASE/5ML
Discontinued
CEFPODOXIME PROXETIL
cefpodoxime proxetil
PHARMACIA AND UPJOHN
"
TABLET; ORAL
EQ 100MG BASE
Discontinued
CEFPODOXIME PROXETIL
cefpodoxime proxetil
PHARMACIA AND UPJOHN
50674
2007-06-07 Letter
2007-06-07 Label
2004-06-07 Label
2004-06-07 Letter
1998-11-20 Letter
1998-11-20 Review
TABLET; ORAL
EQ 200MG BASE
Discontinued
CEFPODOXIME PROXETIL
cefpodoxime proxetil
PHARMACIA AND UPJOHN
"
Drug Adverse Effects information for VANTIN
Role code
Indications
Reaction
# Reports
C
OSTEOPOROSIS
ASTHENIA
1
C
OSTEOPOROSIS
CAST APPLICATION
1
C
OSTEOPOROSIS
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
1
C
OSTEOPOROSIS
COR PULMONALE
1
C
OSTEOPOROSIS
FEELING ABNORMAL
1
C
OSTEOPOROSIS
LEG AMPUTATION
1
C
OSTEOPOROSIS
MENTAL DISORDER
1
C
OSTEOPOROSIS
OVERDOSE
1
C
OSTEOPOROSIS
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE
1
C
OSTEOPOROSIS
PERIPHERAL VASCULAR DISORDER
1
C
OSTEOPOROSIS
PLEURAL EFFUSION
1
C
OSTEOPOROSIS
PNEUMONIA
1
C
OSTEOPOROSIS
PULMONARY HAEMORRHAGE
1
C
OSTEOPOROSIS
WRONG TECHNIQUE IN DRUG USAGE PROCESS
1
Ads by Google